HOME >> BIOLOGY >> NEWS
NIH awards $20.7 million to make smallpox vaccine safer

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a five-year, $20.7 million grant to National Jewish Medical and Research Center to lead a consortium of academic medical centers trying to make smallpox vaccines safer for millions of people with atopic dermatitis, also known as eczema.

"People with a history of atopic dermatitis and people who live with them do not receive smallpox vaccines because atopic dermatitis patients and former patients face an increased risk of developing serious and potentially fatal reactions to the vaccine," said Donald Leung, M.D., Ph.D. Head of the Division of Pediatric Allergy-Clinical Immunology at National Jewish, and principal investigator for the Clinical Studies Consortium of the Atopic Dermatitis and Vaccinia Network. "Our consortium will seek to understand their susceptibility and develop protocols that will allow them to be vaccinated against this potential bioterrorist threat." Erwin Gelfand, M.D., Chairman of Pediatrics at National Jewish, will conduct animal studies in association with the Animal Studies Consortium of the network.

Long a dreaded scourge of humans, smallpox was wiped out around the world by 1980 due to an aggressive vaccination program. Routine vaccinations in the United States ended in 1972. Although the only known stocks of the smallpox virus are contained in laboratories in the United States and Russia, government and health officials fear that others may have the virus and use it as a terrorist weapon. As a result, military and healthcare professionals have begun receiving smallpox vaccinations for the first time in more than 30 years. In the case of an actual smallpox outbreak, thousands and possibly millions of people would receive the vaccine. People with atopic dermatitis do not currently receive the vaccine because they are susceptible to developing eczema vaccinatum, a severe and potentially fatal skin disease caused
'"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
19-May-2004


Page: 1 2 3

Related biology news :

1. Chemical engineering grad students will take notable national awards
2. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
3. NSF awards 22 new projects for plant genome research
4. The American Phytopathological Society announces 2004 awards
5. NSF announces six FIBR awards to tackle some of biologys most challenging questions
6. Two Virginia Tech energy-related inventions win R&D 100 awards
7. APS awards more than $140,000 to minority students of physiology
8. APS awards more than $36,000 to its 2004 undergraduate research fellows
9. 8 environmental stewards win $900,000 in biodiversity awards
10. UCSB professor and director receives two national awards
11. NSF awards $10 million in grants to ocean sites for long-term ecological research

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH awards million make smallpox vaccine safer

(Date:5/14/2015)... , May 14, 2015 Research and Markets ... of the "Fingerprint Sensors Market in Smart Mobile ... This report believes that 2014 was a watershed year ... Apple,s introduction of ,Apple Pay,. Apple gave fingerprint sensors ... mobile payment service. Fingerprint sensors are a must-have feature ...
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... San Francisco, CA (PRWEB) May 21, 2015 ... microbiome sequencing, has announced a partnership with PicnicHealth, ... records for patients. Participants diagnosed with Inflammatory Bowel ... as well as a complementary uBiome research kit. ... Summer 2014. , For more ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
Cached News: